Crispr Innovators Make It Easier to Use Their Gene-Editing Technology
- Broad Institute, Merck KGaA unit set up a one-stop IP shop
- Goal is to speed research into vital gene-editing technologies
This article is for subscribers only.
Two important developers of the celebrated Crispr gene-editing technology said they will make it easier for researchers to license their intellectual property, a move aimed at hastening innovation in the burgeoning field.
MilliporeSigma, the life-sciences tools division of German pharmaceutical giant Merck KGaA, and the Broad Institute of MIT and Harvard said researchers will be able to get nonexclusive rights to patents held by both organizations for research purposes with a single license.